ArticleProceedings of the National Academy of Sciences of the United States of America2024
Femtosecond pulsed laser photodynamic therapy activates melanin and eradicates malignant melanoma.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 20 citations in OpenAlex.
- Photodynamic immune stimulation eradicates primary pigmented melanoma and induces long-lasting anti-tumor immunity.British journal of cancer · 2026Article
- Overcoming Biophysical Barriers in Melanoma Photomedicine: From Photodynamic Therapy to Smart Nanodelivery and Photoimmunotherapy.International journal of molecular sciences · 2026Review
- Potential of Nanoparticle-Based Phototherapies for Future Treatment of Uveal Melanoma.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Photodynamic Therapy for Keratinocytic Precancerous Lesions and Non-Melanoma Skin Cancer: A Narrative Review.International journal of molecular sciences · 2026Review
- Photo-immunotherapeutic PDA-Ce6-R837 nanoparticles enhance the induction of immunogenic responses in melanoma cells.RSC advances · 2026Article
- Article
- Aggregation-Induced-Emission Luminogens Functionalized MXene Nanosheets for Stimuli-Responsive Hydrogel in Pyroptosis-Mediated Choroidal Melanoma Therapy.Nano-micro letters · 2026Article
- Combination of YAP inhibition and photodynamic therapy induces dual DNA damage and activates STING pathway to enhance immunotherapy in uveal melanoma.Redox biology · 2026Article
- Pioneer of Biomedical Optics: Brian C. Wilson.Journal of biomedical optics · 2025Article
- Comparative analysis of ALA mediated sonodynamic therapy considering tumor size, light combination and ultrasound delivery in murine cutaneous melanoma.Scientific reports · 2025Article
- Nanomedicine-Based Treatments for Rare and Aggressive Ocular Cancers: Advances in Drug Delivery.Current treatment options in oncology · 2025Review
- Emerging ultrafast technologies in biotechnology.3 Biotech · 2025Review
- Integrating single-cell omics and materials science for uveal melanoma: from mechanistic insights to precision therapeutics.Frontiers in oncology · 2025Review
- Targeting ocular malignancies using a novel light-activated virus-like drug conjugate.Advances in ophthalmology practice and researchReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 3 countries.
Funding
Abstract
Photodynamic therapy (PDT) relies on a series of photophysical and photochemical reactions leading to cell death. While effective for various cancers, PDT has been less successful in treating pigmented melanoma due to high light absorption by melanin. Here, this limitation is addressed by 2-photon excitation of the photosensitizer (2p-PDT) using ~100 fs pulses of near-infrared laser light. A critical role of melanin in enabling rather than hindering 2p-PDT is elucidated using pigmented and non-pigmented murine melanoma clonal cell lines in vitro. The photocytotoxicities were compared between a clinical photosensitizer (Visudyne) and a porphyrin dimer (Oxdime) with ~600-fold higher σ
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.